IWM
LOGC

IHT Wealth Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

IHT Wealth Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,225
Closed -$61K – 869
2021
Q3 		$61K Sell
13,225
-325
-2% -$1.43K 0.01% 787
2021
Q2 		$60K Buy
13,550
+2,290
+20% +$11.7K ﹤0.01% 922
2021
Q1 		$82K Hold
11,260
– – 0.01% 810
2020
Q4 		$86K Sell
11,260
-200
-2% -$1.34K 0.01% 725
2020
Q3 		$104K Sell
11,460
-200
-2% -$1.52K 0.01% 629
2020
Q2 		$99K Hold
11,660
– – 0.01% 561
2020
Q1 		$58K Buy
+11,660
New +$90.7K 0.01% 529

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

IHT Wealth Management's LOGC Position: Q4 2021 in Review

IHT Wealth Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2021, closing a stake of 13,225 shares — an estimated $61K sold.

IHT Wealth Management first reported a position in LOGC in Q1 2020 and held it in 7 quarters. The position peaked at $104K in Q3 2020. 57 funds tracked by Wall St. Rank hold LOGC as of Q4 2021.

  • IHT Wealth Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • IHT Wealth Management sold 13,225 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $61K.
  • IHT Wealth Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
  • IHT Wealth Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $104K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2021.

Based on IHT Wealth Management's 13F filing for Q4 2021, filed 14 Feb 2022.